Blueprint Medicines (BPMC) Gets a Buy Rating from Raymond James
In a report issued on June 12, Dane Leone from Raymond James maintained a Buy rating on Blueprint Medicines (BPMC). The company’s shares closed last Tuesday at $76.99.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 13.7% and a 63.2% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Ayala Pharmaceuticals, and Magenta Therapeutics.
Blueprint Medicines has an analyst consensus of Strong Buy, with a price target consensus of $98.40, implying a 27.7% upside from current levels. In a report issued on June 8, BMO Capital also maintained a Buy rating on the stock with a $111.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $87.43 and a one-year low of $43.29. Currently, Blueprint Medicines has an average volume of 608.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.